Table 1 Correlation between clinicopathological features and each intrinsic subtype in 237 patients treated with NAC
Parameters | Intrinsic subtype | p-value | |||
|---|---|---|---|---|---|
Luminal (n = 93) | Luminal-HER2 (n = 21) | HER2-enriched (n = 43) | TNBC (n = 80) | ||
Age at operation | |||||
 ≤ 56 | 48 (51.6%) | 12 (57.1%) | 18 (41.9%) | 39 (48.8%) |  |
 > 56 | 45 (48.4%) | 9 (42.9%) | 25 (58.1%) | 41 (51.2%) | 0.641 |
Menopause | |||||
 Pre- | 42 (45.1%) | 9 (42.9%) | 15 (34.9%) | 29 (36.3%) |  |
 Post- | 51 (54.9%) | 12 (57.1%) | 28 (65.1%) | 51 (63.7%) | 0.564 |
Tumor size (cm) | |||||
 ≤ 2 | 13 (14.0%) | 5 (23.8%) | 5 (11.6%) | 9 (11.3%) |  |
 > 2 | 80 (86.0%) | 16 (76.2%) | 38 (88.4%) | 71 (88.7%) | 0.546 |
Lymph node status | |||||
 Negative | 20 (21.5%) | 9 (42.9%) | 14 (32.6%) | 22 (27.5%) |  |
 Positive | 73 (78.5%) | 12 (57.1%) | 29 (67.4%) | 58 (72.5%) | 0.206 |
Nuclear grade | |||||
 1, 2 | 76 (81.7%) | 18 (85.7%) | 35 (81.4%) | 65 (81.3%) |  |
 3 | 17 (18.3%) | 3 (14.3%) | 8 (18.6%) | 15 (18.7%) | 0.969 |
Ki67 (%) | |||||
 ≤ 14 | 34 (36.6%) | 11 (52.4%) | 15 (34.9%) | 19 (23.8%) |  |
 > 14 | 59 (63.4%) | 10 (47.6%) | 28 (65.1%) | 61 (76.2%) | 0.066 |
Pathological response | |||||
 Non-pCR | 70 (73.8%) | 15 (71.4%) | 19 (44.2%) | 42 (52.5%) |  |
 pCR | 23 (26.2%) | 6 (28.6%) | 24 (55.8%) | 38 (47.5%) | 0.001 |